Project Grant R44CA302113
Award Date 9/19/25
Completion Date 8/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), has awarded a $658,336 Project Grant to Rarecyte, Inc. to develop an "ORION2" approach for highly multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis. The project aims to extend Rarecyte's existing ORIONTM technology, which can collect 18-20 plex immunofluorescence data and diagnostic-grade H&E imaging on the same tissue...
- This Project Grant award from the National Cancer Institute's (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a research project titled "Innovative Scan Protocols with Combined Long Axial FOV PET and Spectral CT for Improved Quantification in Oncology". The $666,670 award, effective January 15, 2025, aims to develop advanced imaging protocols and processing techniques that utilize both positron emission tomography (PET) and spectral computed tomography (CT) to enhance...
- The University of Michigan has been awarded a $568,151 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a real-time functional imaging platform for accurate diagnosis and prognosis of prostate cancer. The project aims to leverage photoacoustic imaging and biocompatible hydrogel nanoparticle probes to quantitatively assess prostate gland microarchitecture and tumor microenvironment as imaging biomarkers for improved prostate...
- The National Cancer Institute (NCI) awarded a $606,950 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Pulse Biosciences, Inc. on September 15, 2025. The grant supports the development of a novel two-component treatment for pancreatic ductal adenocarcinoma (PDAC) that combines the use of endoscopic ultrasound-guided delivery of nanosecond electric pulses to the tumor and injection of an immune system stimulant. The goal is to trigger immunogenic cell...
- This $1,838,732 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Nuvox Pharma, L.L.C. supports research to evaluate liquid biopsy approaches for differentiating pseudoprogression from true disease progression in glioblastoma (GBM) patients treated with chemoradiation and an oxygen therapeutic. The key objectives are to 1) determine if the oxygen therapeutic dodecafluoropentane emulsion (DDFPE) alters biomarkers associated with...
- The National Cancer Institute, through the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $450,904 Project Grant to Battelle Memorial Institute's Pacific Northwest National Laboratory. The grant funds the development of a single-cell (phospho-)proteomics platform to enable robust, rapid analysis of individual cells within the tumor microenvironment at both the proteome and phosphoproteome levels. This innovative platform aims to address key challenges in single-cell...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $697,317 to support the development of the MasSpec Pen (MSPen) technology to guide surgical decisions for patients with ovarian cancer. The MSPen is an innovative approach that rapidly and non-destructively analyzes tissue samples during surgery to identify high-grade serous ovarian cancer with 96% accuracy. The funding will enable intraoperative testing and implementation...
- The National Cancer Institute (NCI) awarded Darwin Biosciences, Inc. a $399,998 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. This device will incorporate sample collection, nucleic acid biomarker detection via recombinase polymerase amplification, and visual readout on lateral flow strips. The project aims to address the significant unmet...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded Omnecoil Instruments, Inc. a $399,995 Project Grant to fund the feasibility testing of a novel system for integrated endorectal MRI and in-bore biopsy for prostate cancer diagnosis. The grant aims to develop the Omnecoil system, which consists of a disposable endorectal coil and multichannel needle guide, to allow for endorectal MRI imaging and in-bore MRI-guided...